PeptideJournal
Guides19 min read

Peptides for Bodybuilding: Science vs. Hype

Peptides are everywhere in bodybuilding. Scroll through any fitness forum, and you will find detailed protocols for growth hormone secretagogues, healing peptides, fat-loss fragments, and myostatin inhibitors -- often presented with the confidence of established medical fact.

Peptides are everywhere in bodybuilding. Scroll through any fitness forum, and you will find detailed protocols for growth hormone secretagogues, healing peptides, fat-loss fragments, and myostatin inhibitors -- often presented with the confidence of established medical fact. The reality is different. Most peptides used in bodybuilding have never been tested in resistance-trained athletes. Some have never been tested in humans at all.

That does not mean peptides are worthless. It means the gap between what is claimed and what is proven is unusually wide. This guide evaluates every major peptide category used in bodybuilding based on published clinical research. Where human data exists, we report it. Where it does not, we say so clearly.

Table of Contents

How Peptides Are Used in Bodybuilding

Bodybuilders use peptides with four goals in mind: building muscle, losing fat, recovering from injuries faster, and optimizing growth hormone levels. The logic is straightforward -- peptides can influence hormones and biological pathways involved in all four processes.

The problem is that influencing a pathway and producing a meaningful physical outcome are not the same thing. Raising growth hormone levels in a blood test does not automatically translate to bigger muscles. Accelerating tendon repair in a rat does not guarantee the same effect in a human shoulder. This distinction -- between biomarker changes and real-world outcomes -- is where most peptide claims fall apart.

A 2025 review paper in the Journal of Genesis Publishing summed it up directly: "While peptides offer enticing potential for athletic body recomposition via recovery support, fat metabolism, and anabolic stimulation, current scientific validation is preliminary and fragmentary. Their appeal is heightened by narratives of safer, 'natural' alternatives to traditional agents, yet these are often fueled by anecdotal reports and marketing rather than evidence" [1].

With that context, here is what the research actually shows for each category.

Growth Hormone Secretagogues

Growth hormone secretagogues (GHSs) are the most popular peptide category in bodybuilding. They stimulate your pituitary gland to release more growth hormone, either by mimicking ghrelin (GHRP pathway) or growth hormone-releasing hormone (GHRH pathway). The theory: elevated GH and IGF-1 drive muscle growth, fat loss, and recovery.

Growth hormone does play a role in body composition. But there is a critical gap: no published study has tested any GHS in bodybuilders or well-trained strength athletes [2]. Every claim about these compounds building muscle in experienced lifters is extrapolated from studies in elderly adults, GH-deficient patients, or lab animals.

CJC-1295

CJC-1295 is a synthetic GHRH analog that stimulates pulsatile GH release. It comes in two forms: CJC-1295 with DAC (Drug Affinity Complex, which extends its half-life to 6-8 days) and modified GRF 1-29 (often called "CJC-1295 without DAC"), which has a shorter duration.

What the human data shows:

The key published study is Teichman et al. (2006), involving healthy adults aged 21-61. A single injection of CJC-1295 with DAC produced dose-dependent GH increases of 2- to 10-fold for six or more days, and IGF-1 increases of 1.5- to 3-fold for 9-11 days. Multiple doses showed cumulative effects [3].

This is legitimate pharmacology -- CJC-1295 clearly raises GH and IGF-1 in humans. But the study measured hormone levels, not muscle growth, strength, or body composition. No follow-up study has tested whether these hormone changes translate into meaningful physique outcomes in healthy, trained individuals.

What happened to clinical development:

CJC-1295 with DAC was being investigated for growth hormone deficiency and lipodystrophy and reached Phase 2 trials. Development was halted after a trial participant died. The attending physician attributed the death to pre-existing asymptomatic coronary artery disease rather than the drug, but research was terminated as a precaution [4]. No further clinical development has occurred.

Ipamorelin

Ipamorelin is a synthetic pentapeptide that stimulates GH release by mimicking ghrelin at the GHS receptor. Its defining feature is selectivity: unlike other ghrelin mimetics, ipamorelin raises GH without significantly affecting cortisol or ACTH, even at doses more than 200 times the effective dose for GH release [5].

This selectivity is what makes it popular -- the idea is that you get GH stimulation without the cortisol spike or appetite surge seen with GHRP-6 or GHRP-2. But the human clinical data on ipamorelin is limited to pharmacokinetic studies using short IV infusions in controlled settings. There are no published trials examining ipamorelin's effects on muscle mass, strength, fat loss, or recovery in any population [5].

The CJC-1295 / Ipamorelin Stack

This is the most commonly discussed peptide combination in bodybuilding forums. The rationale makes pharmacological sense: CJC-1295 provides a sustained GHRH signal (the "gas pedal" for GH release), while ipamorelin provides a ghrelin-mimetic signal (releasing the "brakes"). Together, they should produce a more robust and physiological GH pulse than either alone.

The evidence problem:

No published, peer-reviewed study has tested the CJC-1295/ipamorelin combination in any human population for any outcome. The entire evidence base for this stack consists of individual pharmacology studies for each peptide separately, plus extrapolation. Claims about its muscle-building or fat-loss effects are based entirely on anecdotal reports and theoretical reasoning.

One preclinical study showed that CJC-1295 combined with ipamorelin improved maximum tetanic tension in mice with glucocorticoid-induced muscle loss [6]. That is promising, but a mouse study of muscle rescue in a disease model is a long way from evidence that the combination builds muscle in healthy lifters.

MK-677 (Ibutamoren)

MK-677 is the only orally active GHS with substantial human trial data. It is technically not a peptide but a non-peptide ghrelin receptor agonist, though it is universally discussed alongside peptides in bodybuilding contexts.

The landmark study:

Nass et al. (2008) conducted a 2-year, double-blind, placebo-controlled trial in 65 healthy adults aged 60-81. At 25 mg/day, MK-677 increased GH secretion to young-adult levels and increased fat-free mass (FFM) by 1.1 kg over 12 months, versus a 0.5 kg loss with placebo (P<0.001) [7].

The critical finding: no change in muscle strength or physical function was observed. The 1.1 kg FFM increase did not translate into improved performance on any measure. Part of this gain may reflect intracellular water retention rather than new contractile tissue [2].

MK-677 also reversed diet-induced nitrogen loss in a separate study [8], but that involved caloric restriction, not resistance training. Fasting glucose increased by about 5 mg/dL and insulin sensitivity worsened -- a metabolically unfavorable trade-off for minimal functional gains [7].

MK-677 is not FDA-approved and is prohibited by WADA.

GHRP-2 and GHRP-6

GHRP-2 and GHRP-6 are older ghrelin mimetics that reliably stimulate GH release but are less selective than ipamorelin. Both significantly increase appetite (GHRP-6 is notorious for this), and both raise cortisol and prolactin -- side effects that bodybuilders generally want to avoid [9].

Human data for both is limited to pharmacokinetic and acute GH response studies. No published trials have examined their effects on muscle mass, strength, or body composition in any population.

Hexarelin

Hexarelin is the most potent of the ghrelin mimetics for acute GH release. In pharmacological studies, it produces higher GH peaks than GHRP-2 or GHRP-6. But it also shows rapid tachyphylaxis -- the GH response diminishes significantly with repeated use, often within days to weeks [10].

This makes hexarelin poorly suited for the sustained GH elevation bodybuilders seek. It also raises cortisol and prolactin. Human data is limited to acute dosing studies; there are no trials on body composition outcomes.

Sermorelin

Sermorelin is a 29-amino acid GHRH analog that was FDA-approved for diagnosing and treating growth hormone deficiency in children (though this approval was later withdrawn for commercial, not safety, reasons). It stimulates natural, pulsatile GH release.

Among the GH-pathway peptides, sermorelin has the most human clinical data, though still not in bodybuilding contexts. Studies in GH-deficient and aging populations have shown modest improvements in body composition, sleep quality, and bone density [11]. Its effects are milder than exogenous GH, which bodybuilders generally view as a disadvantage -- but it also carries fewer risks of GH excess.

Healing and Recovery Peptides

Recovery from training and injuries is the second major reason bodybuilders turn to peptides. Two compounds dominate this category.

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide originally isolated from human gastric juice. It has generated enormous excitement in the bodybuilding community for its reported ability to heal tendons, ligaments, muscles, and gut tissue.

What the research actually shows:

A 2025 systematic review published in the Orthopaedic Journal of Sports Medicine searched databases from inception through June 2024 and identified 36 studies -- 35 preclinical (animal) and exactly one human study [12].

The animal data is genuinely impressive. In muscle, tendon, ligament, and bone injury models, BPC-157 improved functional recovery, structural healing, and biomechanical strength. It appears to work through multiple pathways: upregulating growth hormone receptor expression in tendon fibroblasts, promoting angiogenesis via the VEGFR2/Akt-eNOS axis, and reducing inflammatory cytokines [12, 13].

The human evidence:

The single human study is a 12-patient retrospective case series (no control group, no blinding, no standardized outcome measures) in which 7 of 12 patients with chronic knee pain reported relief lasting more than 6 months following intra-articular BPC-157 injection [12]. This is the lowest tier of clinical evidence. Without a control group, placebo effect, natural healing, and regression to the mean cannot be distinguished from any drug effect.

As of early 2026, there are zero randomized controlled trials of BPC-157 in humans for any indication.

Does BPC-157 build muscle?

No direct evidence supports this. BPC-157 appears to support tissue repair and recovery, not anabolic muscle growth. The theoretical argument is that faster recovery from training-induced damage could allow for greater training volume, but this has never been studied [14].

Safety concerns:

Animal studies report no adverse effects, but human safety data does not exist. Anonymous online users have reported injection site reactions, anxiety, heart palpitations, insomnia, and mood changes [12]. Product quality is a major concern -- BPC-157 is not FDA-approved, and between 12-58% of supplement products have been found to contain undisclosed substances [12].

BPC-157 is banned by WADA, the NFL, UFC, and NCAA.

TB-500 (Thymosin Beta-4)

TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in tissue repair, cell migration, and angiogenesis. Like BPC-157, it is used by bodybuilders and athletes for injury recovery.

The evidence profile is similar to BPC-157: promising animal data for wound healing and tissue repair, but minimal human clinical evidence for the uses bodybuilders care about. Most human studies have focused on cardiac repair and ophthalmology, not musculoskeletal recovery [15].

TB-500 is banned by WADA.

Myostatin Inhibitors

Myostatin is a protein that puts a brake on muscle growth. Block it, and muscle grows beyond its normal limits -- at least, that is what happens in animals. The appeal to bodybuilders is obvious.

Follistatin

Follistatin is a naturally occurring protein that antagonizes myostatin and other TGF-beta family members. In preclinical research, the results are dramatic:

  • Follistatin overexpression increased muscle weight by about 37% in normal mice [16].
  • Transgenic mice expressing high levels of follistatin had muscle mass increases of 194-327% [17].
  • In nonhuman primates, AAV-delivered follistatin produced durable increases in muscle size and strength [18].

Human data:

Follistatin gene therapy (AAV1-FS344) has been tested in small clinical trials for muscular dystrophy patients, where it improved ambulation in some participants [19]. These are gene therapy studies -- a single viral vector injection that produces sustained follistatin expression -- which is fundamentally different from the "follistatin supplements" or injectable follistatin sold in the bodybuilding market.

No over-the-counter or injectable follistatin product has been validated in a rigorous clinical trial for muscle growth. The clinical-grade research uses AAV-mediated gene therapy at doses and through mechanisms that cannot be replicated by subcutaneous injection of a recombinant protein [18].

ACE-031

ACE-031 blocked myostatin and related ligands using a decoy receptor. A Phase 2 trial in Duchenne muscular dystrophy showed a 3.6% lean mass increase after 12 weeks [20]. But the trial was halted due to safety signals -- nosebleeds, gum bleeding, and dilated blood vessels. Development was discontinued. This remains the most relevant clinical data for myostatin inhibition in humans, and it was terminated for safety reasons.

Fat Loss Peptides

GLP-1 Agonists (Semaglutide, Tirzepatide)

GLP-1 agonists were not developed for bodybuilding, but they are increasingly discussed for contest preparation and off-season body composition management.

Semaglutide (Wegovy) produces 15-21% weight loss in trials [21]. Tirzepatide (Zepbound) achieves 20-23% [22]. These are proven fat loss drugs, but roughly 25-40% of weight lost is lean mass [23] -- a serious concern for bodybuilders trying to preserve muscle during a cut.

The 2025 SEMALEAN study found that lean mass dropped about 3 kg at 7 months but then stabilized, while fat mass continued decreasing [24]. Case reports show that combining GLP-1 therapy with resistance training (3-5 days/week) and high protein (1.2-1.7 g/kg/day) can preserve or even increase lean mass [25]. Regeneron's COURAGE trial found that adding anti-myostatin antibodies to semaglutide prevented 50-80% of lean mass loss [26].

For a deeper dive on fat loss peptides, see our best peptides for fat loss guide.

AOD-9604 and Fragment 176-191

AOD-9604 and Fragment 176-191 are both derived from the fat-metabolizing portion of human growth hormone. They are marketed to bodybuilders as "targeted fat burners" that do not affect muscle or insulin sensitivity.

AOD-9604 failed its Phase 2b trial of 536 subjects -- it did not produce statistically significant weight loss versus placebo [27]. Development was terminated in 2007.

Fragment 176-191 has even less evidence. Published human studies do not exist. The clinical data consists entirely of animal studies and the AOD-9604 trials (since AOD-9604 is a stabilized version of this fragment) [28].

Both continue to be sold by peptide vendors. Neither has evidence supporting its use for fat loss in humans.

IGF-1 Variants

IGF-1 LR3 is a modified form of insulin-like growth factor-1 with a longer half-life than native IGF-1. In theory, it promotes muscle cell proliferation and differentiation. In practice, exogenous IGF-1 administration carries risks including hypoglycemia, and its muscle-building effects have not been demonstrated in controlled human studies [29].

IGF-1 LR3 is used in cell biology research. Its use in bodybuilding is based on mechanistic reasoning and anecdotal reports, not clinical trials.

The Evidence Table

This table summarizes the actual state of evidence for each peptide used in bodybuilding. "Proven in lifters" means controlled studies in resistance-trained humans showing body composition or performance improvements.

PeptideRaises GH/IGF-1 in HumansProven Muscle Growth in Any HumansProven in LiftersFDA ApprovedWADA Status
CJC-1295Yes [3]NoNoNoBanned
IpamorelinYes (acute studies) [5]NoNoNoBanned
CJC-1295 + IpamorelinNot studied as combinationNoNoNoBanned
MK-677Yes [7]+1.1 kg FFM (elderly; no strength gain) [7]NoNoBanned
GHRP-2Yes [9]NoNoNoBanned
GHRP-6Yes [9]NoNoNoBanned
HexarelinYes (tachyphylaxis) [10]NoNoNoBanned
SermorelinYes [11]Modest (GH-deficient patients)NoWithdrawnBanned
BPC-157N/A (not GH pathway)NoNoNoBanned
TB-500N/ANoNoNoBanned
Follistatin (supplements)N/ANoNoNoBanned
AOD-9604N/ANoNoNoNot listed
Fragment 176-191N/ANoNoNoNot listed
IGF-1 LR3N/A (is IGF-1)NoNoNoBanned
SemaglutideN/ANo (causes lean mass loss)NoYes (obesity)Banned

The pattern is stark. Not a single peptide used in bodybuilding has been shown to build muscle in trained individuals in a controlled study.

Safety and Regulatory Reality

Product quality is a genuine risk. Peptides from research vendors or unregulated sources carry no quality guarantee. A vial labeled "BPC-157 5mg" might contain a partial fragment, a different compound, or nothing useful. Studies consistently find that a significant percentage of supplement products are contaminated or mislabeled [12].

The FDA has tightened access. In January 2025, the FDA finalized guidance restricting the compounding of peptides that lack USP monographs [30]. Most bodybuilding peptides -- BPC-157, CJC-1295, ipamorelin, AOD-9604 -- are affected. Legal challenges are ongoing, but the regulatory trend is toward less access.

WADA bans cover almost everything. Growth hormone secretagogues, growth factors, and peptide hormones are prohibited at all times. BPC-157 was specifically added to the banned list. If you compete in tested bodybuilding or any WADA-compliant sport, virtually every peptide here is banned [31].

Side effects are poorly characterized. MK-677 -- the one with the most data -- increases appetite, raises fasting glucose, worsens insulin sensitivity, and causes water retention [7]. Long-term risks of chronic GHS use are unstudied.

What Actually Works for Muscle Growth

It is worth putting peptides in context. The interventions with the strongest evidence for building muscle are not novel or exciting, but they are proven:

Resistance training. Progressive overload is the primary driver of hypertrophy. Decades of research support this. No peptide replaces it.

Protein intake. A meta-analysis of 49 studies found that protein supplementation augments muscle mass and strength gains from resistance training, with benefits plateauing around 1.6 g/kg/day [32].

Creatine monohydrate. One of the most studied supplements in sports nutrition. Creatine increases lean mass, strength, and power output across hundreds of studies [33].

Sleep. Growth hormone is primarily released during deep sleep. Chronic sleep restriction impairs muscle recovery and protein synthesis [34].

Testosterone (where clinically indicated). For men with diagnosed hypogonadism, TRT has robust evidence for improving muscle mass and strength [35].

These interventions share something no bodybuilding peptide has: controlled studies in trained humans showing they work.

For more on evidence-based approaches, see our guides on best peptides for muscle growth and recovery, best peptides for athletic performance, and peptide stacking guide.

Frequently Asked Questions

Do peptides actually build muscle?

No peptide used in bodybuilding has been shown to produce meaningful muscle growth in resistance-trained individuals in a controlled study. MK-677, with the most data, increased fat-free mass by 1.1 kg in elderly adults over 12 months but produced no strength gains [7]. Whether even that modest effect would occur in young, trained lifters is unknown -- it has never been studied.

Is BPC-157 worth using for injury recovery?

The animal data for tissue healing is strong, but human evidence is nearly nonexistent -- one 12-patient case series with no control group [12]. If you are considering BPC-157, understand that you are making a decision based on animal research and anecdotal reports, not proven human efficacy. Product quality from unregulated sources is also uncertain.

What about the CJC-1295/ipamorelin stack everyone talks about?

This combination has never been tested in humans. CJC-1295 alone raises GH and IGF-1, and ipamorelin alone raises GH. Whether the combination produces additive effects, and whether those hormone changes translate to muscle growth in trained lifters, is completely unknown. The popularity of this stack is based on pharmacological theory and forum testimonials, not published research.

Can I use semaglutide or tirzepatide for cutting?

These GLP-1 drugs produce significant fat loss (15-23% of body weight), but 25-40% of weight lost is lean mass [23]. For a bodybuilder, the muscle loss during a cut could be counterproductive. If you use one of these medications, aggressive resistance training and high protein intake (1.2 g/kg/day or higher) appear to help preserve muscle [25]. See our best peptides for fat loss guide for a full comparison.

Are peptides safer than steroids?

This comparison is misleading. Anabolic steroids have decades of adverse effect data because they have been widely studied. Bodybuilding peptides mostly lack long-term human safety data. "Less studied" is not the same as "safer."

Will peptides show up on drug tests?

Yes. WADA prohibits growth hormone secretagogues, growth factors, and peptide hormones at all times [31]. BPC-157 has been specifically added to the banned list. If you compete in any tested federation, assume these compounds are detectable.

Which peptide has the best evidence for bodybuilding?

None has strong evidence for bodybuilding-specific outcomes. Tesamorelin has the best evidence for visceral fat reduction, and sermorelin has the most safety data among GH secretagogues, though neither has been studied in bodybuilders.

The Bottom Line

The bodybuilding peptide market is built on promising biology, limited human data, and a massive amount of extrapolation.

GH secretagogues raise hormones -- proven. But MK-677, the only one tested long-term, increased fat-free mass by a kilogram without improving strength. BPC-157 is remarkable in animals but has one uncontrolled human case series. The only myostatin inhibitor tested in humans was pulled for safety reasons. AOD-9604 failed its clinical trial. GLP-1 drugs work for fat loss but carry lean mass trade-offs that matter when muscle preservation is the goal.

None of this means peptides have zero potential. It means the evidence is not there yet. Future studies in trained populations and combination approaches (like GLP-1 plus anti-myostatin agents) may eventually validate some of what the bodybuilding community has been experimenting with.

Until then, the honest assessment is straightforward: progressive resistance training, adequate protein, creatine, sleep, and clinical hormone management where indicated have orders of magnitude more evidence behind them than any peptide sold for bodybuilding. Use them first. If you choose to add peptides, do so with open eyes about what the science supports, what remains unproven, and what the risks are.

This article is for educational purposes only and does not constitute medical advice. Peptide therapies should only be used under the supervision of a qualified healthcare provider. Do not start, stop, or change any medication without consulting your doctor.

References

  1. Chan M, et al. Emerging anabolic and regenerative peptides in athletic body re-composition and bodybuilding: mechanisms of action, dosing strategies, and evidence review. Journal of Genesis Publishing. 2025. Full text

  2. Healthline. Peptides for bodybuilding: efficacy, safety, types, and more. 2024. Full text

  3. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PMID: 16352683

  4. CJC-1295. Wikipedia. Accessed February 2026

  5. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. PMID: 9849822

  6. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. Full text

  7. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9):601-611. PMID: 18981485

  8. Murphy MG, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):320-325. PMID: 9467534

  9. Sinha DK, et al. Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects. Journals of Gerontology: Series A. 2023;78(Suppl 1):38-44. PMC10272984

  10. Arvat E, et al. Preliminary evidence for an antinociceptive effect of GH secretagogue hexarelin in humans. European Journal of Endocrinology. 1997.

  11. Khorram O, et al. Two years of treatment with recombinant human GH-releasing hormone in elderly men. Growth Hormone & IGF Research. 2001.

  12. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Orthopaedic Journal of Sports Medicine. 2025. PMC12313605

  13. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMC6271067

  14. DocCheck. BPC-157 -- mechanism, research evidence, and therapeutic potential. 2025. Full text

  15. Goldstein AL, et al. Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012.

  16. Gilson H, et al. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. American Journal of Physiology-Endocrinology and Metabolism. 2009;297(1):E157-E164. Full text

  17. Lee SJ, et al. Regulation of muscle mass by follistatin and activins. Molecular Endocrinology. 2010;24(10):1998-2008. Full text

  18. Kota J, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science Translational Medicine. 2009;1(6):6ra15. PMC2852878

  19. Mendell JR, et al. Follistatin gene therapy improves ambulation in Becker muscular dystrophy. Journal of Neurology. 2017;264:250-260. PMC5240576

  20. Attie KM, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve. 2013;47(3):416-423.

  21. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. PMID: 33567185

  22. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024

  23. Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(9):4032-4044. PMID: 38937282

  24. Barchetta I, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes, Obesity and Metabolism. 2025. PMID: 41068996

  25. Segar A, et al. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. Obesity Science & Practice. 2025. PMC12536186

  26. Regeneron Pharmaceuticals. Interim results from ongoing Phase 2 COURAGE trial confirm potential to improve the quality of semaglutide-induced weight loss by preserving lean mass. 2025. Press release

  27. Moré MI, et al. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism. 2015;5(4):236-247. Full text

  28. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001;25(10):1442-1449.

  29. Schmid C, et al. IGF-I and IGF binding proteins in the regulation of muscle metabolism. Hormone Research. 1996.

  30. FDA. Interim policy on compounding using bulk drug substances under Section 503A of the Federal Food, Drug, and Cosmetic Act. Federal Register. January 7, 2025.

  31. World Anti-Doping Agency. 2025 Prohibited List. WADA. 2025.

  32. Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine. 2018;52(6):376-384. PMID: 28698222

  33. Kreider RB, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18.

  34. Dattilo M, et al. Sleep and muscle recovery: endocrinological and molecular basis for a new and promising hypothesis. Medical Hypotheses. 2011;77(2):220-222.

  35. Bhasin S, et al. Testosterone dose-response relationships in healthy young men. American Journal of Physiology-Endocrinology and Metabolism. 2001;281(6):E1172-E1181.